MEDICINAL CANNABIS IN AOTEAROA:

Slides:



Advertisements
Similar presentations
Medsafe – GMP update / release for supply / communicating quality issues Derek Fitzgerald Manager, Compliance Management 11 July 2013 RACI Pharmaceutical.
Advertisements

The Health Care Law and. In March 2010, President Obama signed into law the Affordable Care Act. The Health Care Law.
Invest in Future Medicines
International Experience in Pharmaceutical Services for Promoting Access to Medicines: Canada, Cuba, England, Mexico International Seminar on the Challenges.
Making health care reform work for Alabama What the Affordable Care Act means for a high-poverty state Dollie Hambrick Health Reform Organizer Arise Citizens’
Chapter 6 Sourcing. Objectives After reading the chapter and reviewing the materials presented the students will be able to: Explain the difference between.
Welcome to The Green Canvas information session. Today's Topics How current MMAR patients prepare for the new regulations so they are not without medication.
MAIN FEATURES OF WORLD LEGAL AID SYSTEMS PROFESSOR DAVID McQUOID-MASON UNIVERSITY OF KWAZULU-NATAL SOUTH AFRICA.
Intellectual Property Rights and Pharmaceuticals (Following Up the ‘Novartis case’ ) Background note prepared for PHM Vic Internet Workshop.
University of Wisconsin Pain & Policy Studies Group World Health Organization Collaborating Center for Pain Policy and Palliative Care Action Plan for:
© 2009 Delmar, Cengage Learning Chapter 3 Home Health Care.
Opportunities in 2012 and Beyond The Way Forward Stuart Semple Director of Pharmacy and Medicines Management Barts Health NHS Trust.
Health Care in Australia Medicare and Private Health Insurance.
A Common Assessment Framework for Adults – Development 12 February 2008 Carl Evans Social Care, Local Government and Care Services Directorate Department.
Sheffield prescribing update Public meeting 16 March 2016 Zak McMurray Peter Magirr.
Legalization: When and What _________________________________________________________________________________________________________________________________________________.
Pharmacy White Paper Building on Strengths Delivering the Future Overview.
OLCC Recreational Marijuana Implementation Amanda Borup, Policy Analyst, OLCC Oregon Pesticide Symposium March, 2016.
Iain Shaw Head of Agency and Older People’s Services Older People’s Strategy
Northeast Ohio Healthcare Sector Offers Strong Employment Prospects A Trove of Opportunity:
It’s a big deal Scott Decker, JD, MPH. What the White House Says:  Improved affordability  Helps 32 million uninsured obtain health insurance  Reduces.
“What I want a College of Emergency Medicine to do for me?” FASSGEM Presentation.
The recovery agenda – a pharmacy perspective
Healthcare and the Market
The Czech Health System – its Presence and Future
CQC matters: Regulating the safe and effective use of medicines
Health Reform: What It Means to Our Community
REPORT ON THE MEDICAL CANNABIS REGULATION AND SAFETY ACT AND THE ADULT USE OF MARIJUANA ACT AND RECOMMENDED ACTIONS February 28, 2017.
MAIL ORDER PHARMACY 1.
Disclosure UK Talking about Transparency.
Health Technology Assessment
Some good background information
MARIJUANA IS NOT MEDICINE
Understanding Economics Advanced Marketing
CHANGES TO THE POST-RETIREMENT SUBSIDY FOR SATS PENSIONERS March
CHANGES TO THE POST-RETIREMENT SUBSIDY FOR SATS PENSIONERS March
Palliative Care in Canada: History, Vision and Challenges
HEALTH CARE POLICY.
Integrating Clinical Pharmacy into a wider health economy
CHANGES TO THE POST-RETIREMENT SUBSIDY FOR SATS PENSIONERS March
Disclosure UK Talking about Transparency.
Canada Needs PAs.
Minor Uses A North American Perspective
Canada Needs PAs.
Medicinal Cannabis Reform Workshop
MEDICAL CANNABIS 101.
Providing sustainable resilient primary care
Lisbon Addictions 2017, October, Lisbon Mafalda Pardal
Large Scale Cannabis Cultivation: the Case of the Netherlands
THE GOVERNMENT MEDICINAL CANNABIS BILL
Health Technology Assessment
Rural Track orientation
Canada Needs PAs.
Canada Needs PAs.
Canada Needs PAs.
2019 Medicare Part D Rule Opioid-related Provisions
Imagine that you're one of the estimated 36 million adults in the U. S
Health Care Policy Public Policy.
Pharmacy – Fully Insured versus Self Funding
Canada Needs PAs.
Canada Needs PAs.
Component 1: Introduction to Health Care and Public Health in the U.S.
Worthen Medical Practice
Economic and Fiscal Considerations of Legalized Cannabis
Pharmaceuticals Industry
Canada Needs PAs.
The Chronic Care Model Overview
Let’s talk medicines safety
Mental Health Navigator
Access to Cannabis for Medicinal and Research Purposes
Presentation transcript:

MEDICINAL CANNABIS IN AOTEAROA: A COMPREHENSIVE SOLUTION FOR 2018 AND BEYOND.

After surveying the Drug law reform community there was an observed need for an official body to advocate for patients exclusively. After an abortive attempt in 2015, Registered a charitable trust in early 2016 First phase was funding Sativex, cute kids frequently raised 10k+ for themselves, not as success full with adults. Second phase was exploiting the “Non Pharmaceutical” Pathway for cheaper products, first success was Tilray, 25-30% cost saving, next step is an inbound product range from Cannimed offering 50% cost savings. 80% of all applications in 2016 were the work of MCANZ. Most Recent phase is a pivot towards political advocacy with 2 Cannabis bills before parliament, and our MC2018 policy booklet. History of MCANZ

MC2018 Policy booklet. Inspired by “Whakawatea-te-Huarahi” from the Drug Foundation, which only briefly covered Medical Cannabis. Contact with NZMA Board members, politicians, local industry startups, illicit growers and international industry experts. 21 Revisions, 2-3 months work.

Background, Unmet demand Canada, which has a scheme that covers a robust industry for products and the ability for patients to grow, has 20k patients licensed to grow, and 200k patients licensed to purchase products Israel, a more conservative model, has 30k for a population of 8 million. At the time of writing, best estimate from talking to suppliers was about 70 patients. With the expansion of CBD that number is closer to 120 If we follow a Canadian Regime, and matched there current numbers, we would have 25k patients, 15k for Israel.

Phase 1, the interim changes Schedule 22 of the MODR means Medicinal Cocaine, Opium are easier to prescribe than Cannabis. Rather than a defence for Terminal cases, we suggest a blanket “Medical necessity defence”. MOH to initiate a round of training for prescribers. As a unregistered range of medicines with wide range of uses, education is key, many GPs are holding back until they know more. Summary, GPs get free reign and education, patients get a free ride from the courts.

The Bones of the legal Framework Preparations currently go to class B Deschedule all non psychoactive compounds, not just CBD Low Dose CBD products to go to pharmacies. Manufacture to standards similar to Canadian GPP

Medical Cannabis as a Medical specialty WHO studies suggest changing prescribing habits of older doctors is futile. Even countries with liberal attitudes have a very small pool of prescribers, it is lucrative. In Canada some prescribers are reckless, doing skype consults with 0 follow up etc, and are being reprimanded NZ already has a GP who has single handedly prescribed more CBD than anyone else in Australia NZ, - responsibly To circumvent these practices, rather than chastise those “pro pot prescribers” Set up standards for prescribers to be “specialists” Rather than dispensaries run by lay people, this group of prescribers could have a variety of stock on hand to perform a function as a “dispensary lite” “Specialist” status entails high competency, cultivating expertise, and increased oversight by the MOH in exchange for a desirable status for the prescriber. – Carrot and stick.

Licensed producers American systems are prone to diversion to the illicit market, with separate licenses for growers, manufacturers and retail. Canadian Licensed producers provide All in one solution “Vertically integrated”. Advantages in security, quality control (product recalls!) and economies of scale.

Product classifications Canada and USA operate on a permit basis, patient decides what cannabis and how to use it. Australia, NZ, UK etc are focusing on products. With a vast array of strains on hand, the 2 issues methods need merging. Doctors are not going to be writing out scripts for Alaskan thunderf*** or Green Crack for example.

Product Bands Cannabis is broken into classification groups for prescribing based on strength and Ratio Patient has a choice of strains in that group Australia, NZ, UK etc are focusing on products. With a vast array of strains on hand, the 2 issues methods need merging. Doctors are not going to be writing out scripts for Alaskan thunderf*** or Green Crack for example.

Vaporizers Currently Vaporizers are drug utensils. Vaporizers minimize the harms from smoking Cannabis, from at least 80% for the cheap units, but 90%+ for the higher end units. Some Vaporizers are registered medical Devices in other jurisdictions Legalize them all – huge population level harm reduction.

Patient Subsidies Imported products for Epilepsy could cost as much as 100k a year for a teenager with a severe form of epilespy. Local products could still cost 10s of thousands PHARMAC requires multiple phase 3 clinical trials to fund or in the case of Med Can, “pigs to fly” MCANZ proposal is for Taxes generated from Licensed producers be ring fenced for funding patients. Pharmac to administer a separate scheme where emerging evidence and patient efficacy is taken into account, if a patient has epilepsy and has a successful trial, then this scheme can absorb the ongoing costs.

Home grow Setting up local products will take years, in the mean time patients will continue to grow. Doctors barely prescribe MC, let alone dealing with permits for patients to grow. Licensing agency would certify individual patients to grow their own. Criteria would be clinical evidence, ethics review, and criminal background checks. Permits would be time limited, and after assessing the patients needs, a permit would be granted.

Questions ?

Permits Permits would be for a size of area, not plant counts. The permitted area for the patient could be transferrable to a green fairy or compassionate grower. Compassionate Growers would be held to a higher standard, intent would be similar to foodgrade, to ensure they are not reckless with the production and quality control of products. For example, West Coast Green Fairy supplies a few people in Westport. He has a handful of chronic pain patients who have been granted 2m2 each, and 2 cancer patients who have been granted 4m2 each. The toal amount he is aloud is 20m2, he buys indoor grow tents to cover half those needs, and then has an outdoor greenhouse of 10m2 in size. He has annual inspections to ensure he isn’t “overgrowing” and he periodically has his product sent off for testing to ensure his products have low levels of mold, and that he isn’t using any banned pesticides.

Timeline

Questions?